ArticleJournal of cardiovascular development and disease2026
Pressure-Adjusted Heart Rate Predicts Mortality and Resource Utilization in Cardiogenic Shock: An Analysis of the MIMIC-IV Database.
Article in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPressure-Adjusted Heart Rate (PAHR) is a novel hemodynamic index in cardiogenic shock (CS); however, its dynamic outcome remains underexplored.
methodsIn this retrospective cohort study, which utilized the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, PAHR was calculated using at least 12 time-matched values of mean arterial pressure (MAP), central venous pressure (CVP), and heart rate (HR) over the first 48 h. Patients receiving early mechanical circulatory support (MCS) were excluded. Multivariable regression assessed PAHR's association with mortality, requirement of renal replacement therapy (RRT), and invasive mechanical ventilation. Effect estimates were reported per 10-unit increments of PAHR.
resultsA total of 772 patients with CS were included. Mean PAHR was 15.9 ± 7.0. In our multivariable analysis, every 10-unit PAHR increase independently predicted in-hospital mortality (adjusted OR 1.97; 95% CI 1.45-2.68;
conclusionPAHR is a promising integrated marker of mortality and morbidity in patients with CS. It serves as a sustained predictor of outcomes, though external validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.